COVID-19News

COVAXIN (BBV152) booster dose study shows promising results 

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, announced the results from the highly anticipated trial studying the immunogenicity and safety of the COVAXIN (BBV152) a whole-virion inactivated COVID-19 vaccine as a booster dose. 

THIS CAN BE YOUR ADVERTISEMENT

This analysis re-emphasises Bharat Biotech’s continued efforts to stay ahead of COVID-19, and this update provides a comprehensive vaccine booster strategy. COVAXIN is the first vaccine (in India) to report safety and immunogenicity results from a booster clinical trial. The analysis showed, six months after a two-dose BBV152 vaccination series cell-mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined. 

Furthermore, Neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19 to 265 fold after a third vaccination. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections. 

Dr Krishna Ella, CMD, Bharat Biotech, said, “These trial results provide a strong foundation towards our goal to provide COVAXIN as a booster dose. Our goal of developing a global vaccine against COVID-19 have been achieved. COVAXIN is now indicated for adults, children, 2 dose primary and booster doses. This enables the use of COVAXIN as a universal vaccine.”

We found the vaccine induces both memory B and T cells with a distinct CD4 and CD8 phenotype. Further, reactogenicity after vaccine and placebo was minimal and comparable, and no serious adverse events were reported. While protection against the severe disease remains high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected. Based on emerging data, Bharat Biotech believes that a third dose may be beneficial to maintain the highest levels of protection. 

COVAXIN is formulated uniquely such that the same dosage can be administered to adults and children alike. COVAXIN is ready-to-use a liquid vaccine, stored at 2- 8°C, with 12 months shelf life and a multi-dose vial policy. The same vaccine can also be used for two-dose primary immunisation and for booster dose vaccinations, making it truly a universal vaccine. 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close